David Moskowitz on AI and the Future of Drug Discovery
In the final episode of our four-part series in our discussion with David Moskowitz of 8VC, Daniel Haders II, Ph.D. asks David to describe how he sees the future of AI in drug discovery unfolding, and more broadly, what impact does AI and machine learning have on the pharmaceutical sector writ large.
In Today’s Episode You Will Learn
Where does David see the AI drug discovery industry going, and what market dynamics impact the players in the space?
David shares his perspective about technology that is a tool that may allow you to do something faster versus technology that is a platform and can change business models.
Does David see a future for vertically integrated, digital first pharmaceutical companies, like Model Medicines, who utilize AI in clinical trials and post approval real world evidence data analysis?
David Moskowitz focuses on the Bio-IT space. Prior to joining 8VC, David completed his Ph.D. in Biomedical Informatics at Stanford University, where he concurrently received an M.S. in Statistics. His research focused on the development of statistical and machine learning approaches for analyzing genomics data, and the characterization of epigenetic changes associated with aging in T cells. Previously, David was a Bioinformatic Analyst at Einstein College of Medicine, where he worked on the genetics of aging and human disease. He performed his undergraduate studies in Computational Biology at Brown University.
